Advertisement

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Business

AstraZeneca, Sanofi Cut Programs

by Lisa M. Jarvis
June 10, 2013 | A version of this story appeared in Volume 91, Issue 23

AstraZeneca has ended development of fostamatinib, a spleen tyrosine kinase inhibitor, after two Phase III trials in rheumatoid arthritis patients failed to live up to the potential seen in earlier studies. In 2010, AstraZeneca paid Rigel Pharmaceuticals $100 million up front for access to the drug. The British firm is returning the rights to Rigel and will take a $140 million charge to its second-quarter R&D expenses for the pipeline loss. Separately, Sanofi is ending development on two compounds, the anticancer compound iniparib and the anticoagulant otamixaban, which both flunked Phase III studies. Sanofi expects the charge related to ditching iniparib will have an impact of $285 million on its net income, but it specified no charge on otamixaban.

Article:

This article has been sent to the following recipient:

0 /1 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.